BiotechTV - News - TopPodcast.com

Latest Episodes:

SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more Jan 12, 2026

Show notes

He discusses regulatory feedback the company has received that might allow it to earn an accelerated approval in antitrypsin deficiency. Plus, filing for sickle cell later this year, and how he thinks about new targets.

SF Healthcare Week: Flagship Pioneering's Founder Noubar Afeyan shares his thoughts on the image of science in the United States today, biotech's roller coaster 2025, mRNA, AI, and more Jan 12, 2026

Show notes

He discusses the theme of his annual letter that was published today, "Choosing Science," and why it is important that our country continues to invest in basic research. Plus, his take on the M&A environment in biotech.

SF Healthcare Week: Baird Senior Analyst Brian Skorney comments on Monday's conference news and highlights his top picks ahead for 2026 Jan 12, 2026

Show notes

He discusses Biohaven, Xenon, Biogen, and Sarepta.

SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy Jan 12, 2026

Show notes

Founder and CEO Marshall Fordyce talks about the data that supported the application and describes how atacicept’s novel mechanism holds the potential to transform the treatment of the autoimmune disease. He says the company is getting ready to launch, with a PDUFA date set for July.

SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy Jan 12, 2026

Show notes

He discusses the company's degrader programs, TYK2/JAK1, using myostatin for obesity, and a Kv7 epilepsy program that will have key data this year.

SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year Jan 12, 2026

Show notes

He discusses the company's accomplishments to date, and highlights learnings about the mechanism and important data in 2026 in the maintenance setting for UC and Crohn's later this year.

Mizuho Senior Biotech Analyst Salim Syed highlights key companies in the news he covers heading into the new year Jan 07, 2026

Show notes

He discusses BridgeBio, Cytokinetics, Vaxcyte, Biogen, and Arcus Biosciences

William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026 Dec 30, 2025

Show notes

He discusses the recently approved Wegovy pill, and compares and contrasts it to other oral programs from Lilly, Structure, and Corbus. Plus, how is the amylin space looking compared to GLP-1s, and a preview of Viking's 2026.

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza Dec 29, 2025

Show notes

We discuss the upcoming maintenance data, commercial prospects, Crohn's, and buyout prospects.

Create Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells." Dec 12, 2025

Show notes

Co-Founder and CEO Daniel Getts walks us through the platform, which is delivered via LNPs. The lead programs target TROP2, HER2, and GPC3.